Netherlands· NL-8ffd1589e1c0
Klisyri 10 mg/g, zalf
A tirbanibulin product containing tirbanibuline, registered in Netherlands by Grupo Farmacéutico Almirall S.A.. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Tirbanibulin is registered in 12 of 19 countries.
Countries holding a registration under ATC D06BX03 (tirbanibulin), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Tirbanibulin · ATC D06BX03
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- TIRBANIBULINE
- Manufacturer
- Grupo Farmacéutico Almirall S.A.
- Country
- Netherlands (NL)
- ATC code
- D06BX03
- ATC class
- Tirbanibulin
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1558
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tirbanibulin in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesKlisyriAlmirall, LLC
- SpainKLISYRI 10 MG/G POMADAAlmirall S.A.
- FinlandKlisyriAlmirall S.A.
- CzechiaKLISYRIAlmirall, S.A., Barcelona
- PolandKlisyriAlmirall, S.A.
- SwedenKlisyri 10 mg/g SalvaAlmirall S.A.
- IcelandKlisyriAlmirall S.A.*
- United KingdomKlisyri 10mg/g ointment 250mg sachetsAlmirall Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Klisyri
- Liechtenstein · Klisyri
- Norway · Klisyri
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e057ab24-6b0c-47b1-a841-4b807aca0b39 GET /v1/drugs/e057ab24-6b0c-47b1-a841-4b807aca0b39?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Zalf",
"route": "Cutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/klisyri-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Tirbanibulin",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126337",
"excipients": [
"GLYCEROLMONOSTEARAAT 40-55 (E 471)",
"PROPYLEENGLYCOL (E 1520)"
],
"substances": [
"TIRBANIBULINE"
],
"leaflet_url": null,
"authorised_at": "2021/07/16",
"procedure_number": "EMEA/H/C/005183",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1558",
"additional_monitoring": "Y"
}See everything about tirbanibulin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.